Artificial surfaces

Artificial surfaces refer to non-biological materials, such as polymers, metals, and ceramics, used in medical implants and devices like heart valves, stents, and dialysis membranes. These surfaces are not therapeutic targets in the molecular sense; rather, they are substrates that interact with biological systems, often triggering the contact activation pathway of coagulation and the foreign body response (Gorbet & Sefton, 2004, Biomaterials). The primary clinical challenge associated with artificial surfaces is their inherent thrombogenicity and susceptibility to bacterial colonization, which can lead to device-associated infections or thromboembolic events (Ratner, 2011, J Cardiovasc Transl Res). To mitigate these risks, drugs such as anticoagulants (e.g., heparin) are used either systemically or as surface coatings, and drug-eluting stents utilize agents like sirolimus to prevent neointimal hyperplasia (Tepe et al., 2008, NEJM). Consequently, while artificial surfaces are not targets for drug binding in a traditional pharmacological model, they represent a critical interface where pharmacological intervention is required to ensure device safety and efficacy (Anderson et al., 2008, Semin Immunol). Understanding the molecular events at the bio-interface is essential for the development of next-generation biomaterials with improved long-term performance.

Other names

BiomaterialsSynthetic surfacesProsthetic surfacesMedical device surfaces

Inhibition of the coagulation cascade, prevention of platelet aggregation, suppression of smooth muscle cell proliferation, and antimicrobial activity.